Effects of metabolic syndrome on prostate specific antigen level, prostate volume and international prostate symptom scores in patients with benign prostatic hyperplasia

摘要

Background and objective: Benign prostatic hyperplasia involves the enlargement of prostatic glandular tissue and narrowing of the urethra. It affects bladder storage or emptying. Most of the men with benign prostatic hyperplasia have no symptoms. This study aimed to compare international prostate symptom scores, prostate specific antigen level and prostate volume in patients having benign prostatic hyperplasia with and without metabolic syndrome. Methods: This study involved 85 patients with benign prostatic hyperplasia who were divided into two groups. The first group included 40 participants who were only suffering from benign prostatic hyperplasia and the second group involved 45 participants who were suffering from both metabolic syndrome and benign prostatic hyperplasia. The division of subjects was performed depending on three abnormal parameters out of five parameters, such as body mass index (BMI 25kg/m 2 ), dyslipidemia (Triglyceride ≥150?mg/dl, High density lipoprotein-C 40?mg/dl), blood pressure (BP ≥130/85 mmHg), fasting plasma glucose (PG ≥110?mg/dl). Results: Patients with metabolic syndrome at diagnosis appears to have significantly higher levels of prostate specific antigen comparing with patients without metabolic syndrome, 3.9±0.26 and 2.7±0.21, respectively. Similarly, patients with metabolic syndrome at diagnosis had significantly higher prostate volume levels (72.69 ± 2.69 ml) comparing to patients without metabolic syndrome (46 ± 2.44 ml). Patients with metabolic syndrome at diagnosis showed considerable higher international prostate symptom scores level (23.62 ± 0.62) compared to patients without metabolic syndrome (18.87 ± 0.327). Conclusions: benign prostatic hyperplasia patients having metabolic syndrome have significantly higher values of prostate specific antigen levels, prostate volume and international prostate symptom scores compared to benign prostate hyperplasia patients without metabolic syndrome.